Marshall Wace LLP Has $310,000 Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

Marshall Wace LLP decreased its position in Wave Life Sciences Ltd. (NASDAQ:WVE) by 80.2% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 62,102 shares of the company’s stock after selling 251,303 shares during the period. Marshall Wace LLP’s holdings in Wave Life Sciences were worth $310,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Profund Advisors LLC bought a new stake in shares of Wave Life Sciences during the second quarter worth approximately $53,000. Sei Investments Co. bought a new stake in shares of Wave Life Sciences during the second quarter worth $130,000. Hsbc Holdings PLC bought a new stake in shares of Wave Life Sciences in the second quarter worth $104,000. Emerald Advisers LLC bought a new stake in Wave Life Sciences during the second quarter valued at $12,441,000. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in shares of Wave Life Sciences during the second quarter valued at about $9,086,000. Institutional investors and hedge funds own 89.73% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Mizuho reiterated an “outperform” rating and issued a $19.00 price objective on shares of Wave Life Sciences in a research note on Tuesday, June 25th. Royal Bank of Canada raised their price objective on shares of Wave Life Sciences from $5.00 to $7.00 and gave the company a “sector perform” rating in a research report on Friday, October 4th. HC Wainwright raised their price target on shares of Wave Life Sciences from $15.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, September 25th. JPMorgan Chase & Co. started coverage on shares of Wave Life Sciences in a research note on Friday, September 27th. They set an “overweight” rating and a $13.00 target price on the stock. Finally, B. Riley lifted their target price on shares of Wave Life Sciences from $11.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Insiders Place Their Bets

In other Wave Life Sciences news, major shareholder Plc Gsk bought 2,791,930 shares of the company’s stock in a transaction dated Friday, September 27th. The stock was acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the acquisition, the insider now directly owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Kyle Moran sold 17,146 shares of the stock in a transaction dated Wednesday, September 25th. The shares were sold at an average price of $9.00, for a total transaction of $154,314.00. Following the sale, the chief financial officer now owns 19,777 shares of the company’s stock, valued at approximately $177,993. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Plc Gsk bought 2,791,930 shares of Wave Life Sciences stock in a transaction that occurred on Friday, September 27th. The stock was purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the acquisition, the insider now owns 16,775,691 shares of the company’s stock, valued at $134,205,528. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 29.10% of the stock is currently owned by company insiders.

Wave Life Sciences Stock Performance

NASDAQ:WVE opened at $8.61 on Friday. The stock has a market capitalization of $1.07 billion, a P/E ratio of -15.11 and a beta of -1.10. Wave Life Sciences Ltd. has a fifty-two week low of $3.50 and a fifty-two week high of $9.92. The company’s 50-day simple moving average is $6.44 and its 200-day simple moving average is $6.00.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.09). Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 1,395.99%. The business had revenue of $19.69 million for the quarter, compared to analyst estimates of $24.80 million. During the same quarter in the previous year, the firm posted ($0.20) earnings per share. On average, research analysts forecast that Wave Life Sciences Ltd. will post -1.02 EPS for the current year.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.